| Literature DB >> 34686736 |
Bernardo V Alvarez1, Marilyse Piché2, Carolin Aizouki1, Fariha Rahman1, Jonathan M J Derry3, Isabelle Brunette2,4, Joseph R Casey5,6,7.
Abstract
SLC4A11 is a H+/NH3/water transport protein, of corneal endothelial cells. SLC4A11 mutations cause congenital hereditary endothelial dystrophy and some cases of Fuchs endothelial corneal dystrophy. To probe SLC4A11's roles, we compared gene expression in RNA from corneas of 17-week-old slc4a11-/- (n = 3) and slc4a11+/+ mice (n = 3) and subjected to RNA sequencing. mRNA levels for a subset of genes were also assessed by quantitative real-time reverse transcription PCR (qRT RT-PCR). Cornea expressed 13,173 genes, which were rank-ordered for their abundance. In slc4a11-/- corneas, 100 genes had significantly altered expression. Abundant slc14a1 expression, encoding the urea transporter UT-A, suggests a significant role in the cornea. The set of genes with altered expression was subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, revealing that alterations clustered into extracellular region, cytoskeleton, cell adhesion and plasma membrane functions. Gene expression changes further clustered into classes (with decreasing numbers of genes): cell fate and development, extracellular matrix and cell adhesion, cytoskeleton, ion homeostasis and energy metabolism. Together these gene changes confirm earlier suggestions of a role of SLC4A11 in ion homeostasis, energy metabolism, cell adhesion, and reveal an unrecognized SLC4A11 role in cytoskeletal organization.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34686736 PMCID: PMC8536660 DOI: 10.1038/s41598-021-98921-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Sequencing run mapping statistics.
| Sample ID | Total reads | Mapped reads | % of mapped reads |
|---|---|---|---|
| 24,689,292 | 23,289,622 | 94 | |
| 19,193,868 | 18,485,986 | 96 | |
| 3,457,512 | 3,272,941 | 95 | |
| 22,441,611 | 20,975,724 | 93 | |
| 20,761,849 | 19,899,296 | 96 | |
| 9,316,547 | 8,779,019 | 94 |
Percentage of trimmed and filtered reads successfully mapped to the genome, from total reads sequenced for each sample.
Figure 1 Gene expression profiles for slc4a11+ and slc4a11 corneal RNA samples. Genes significantly down and up regulated in slc4a11 cornea samples are indicated by blue dots. Genes with no significant differential expression are represented by red dots. Dashed lines indicate the boundaries for genes with significantly altered expression. The x-axis represents fold change of gene expression, and the y-axis represents the magnitude of significance of the gene expression changes. Identified gene examples: slc4a11, solute carrier family member 11; frem3, fras 1 related extracellular matrix protein 3; ntr1, netrin 1; pygl, prostaglandin endoperoxidase synthase 1; frem1, fras 1 -related extracellular matrix 1; csgalnact1, chondroitin sulfate N-acetylgalactosaminyltransferase-1; tox, thymocyte selection-associated high mobility group box; mlph, melanophilin; tll1, tolloid-like protein 1; gpr68, G-protein-coupled receptor 68; st8sia4, polysialyltransferase; upp1, uridine phosphorylase 1; ptgs1, liver glycogen phosphorylase 1; krt 14, keratin; krt 15, keratin; glis 3, glis family zinc finger 3; myadm, myeloid associated differentiation marker; fndc1, fibronectin type III domain containing 1; srgap1, slit-robo GTPase-activating protein; sv2c, synaptic vesicle glycoprotein 2; gabra1, gamma-aminobutyric acid receptor A subunit; gabrb2, gaba receptor B subunit.
Gene ontology (GO) enrichment analysis.
| Gene | Protein encoded | Fold change | Gene | Protein encoded | Fold change |
|---|---|---|---|---|---|
| Multimerin 1 | 4.0 | Matrilin 2 | 2.1 | ||
| Sclerostin domain containing 1 | 3.8 | Tolloid-like | 0.10 | ||
| Serine peptidase inhibitor, Kazal 5 | 3.5 | Fras1 related ECM 1 | 0.11 | ||
| Dickkopf WNT pathway inhibitor 1 | 2.9 | Fras1 related ECM 3 | 0.25 | ||
| Collagen, type XIV, alpha 1 | 2.7 | Netrin 1 | 0.29 | ||
| Lysyl oxidase-like 2 | 2.3 | Phospholipase A2, group IIF | 0.29 | ||
| B-1,3-glucuronyltransferase 1 | 2.2 | Tnf receptor 11b | 0.33 | ||
| Lectin, galactose binding, soluble 7 | 2.2 | Complement component 4B | 0.35 | ||
| Collagen, type XIV, alpha 1 | 2.73 | Fras1 related ECM 3 | 0.25 | ||
| Cadherin 3 | 2.33 | Fat atypical cadherin 4 | 0.44 | ||
| Cadherin 13 | 2.32 | RHO family interacting cell polarization regulator 2 | 0.46 | ||
| Fras1 related ECM 1 | 0.11 | ||||
| Tubulin, beta 4A class IVA | 3.32 | Serine/threonine kinase 39 | 2.37 | ||
| Fascin actin-bundling protein 1 | 3.01 | Protein phosphatase 1, regulatory 18 | 2.02 | ||
| Formin homology dom. containing 3 | 2.63 | Espin | 0.25 | ||
| Microtubule-associated protein 1B | 2.44 | See above | 0.46 | ||
| GABA A receptor, alpha 1 | 17.58 | Smoothened receptor | 2.01 | ||
| GABA A receptor, beta 2 | 6.74 | Cholinergic R., nicotinic, b- 3 | 0.03 | ||
| V-set containing T cell activation inhibitor 1 | 3.24 | Solute carrier family 4 member 11 | 0.06 | ||
| Fascin actin-bundling protein 1 | 3.01 | GPCR 68 | 0.12 | ||
| D like non-canonical Notch ligand 2 | 2.78 | Cytochrome P450, family 24, 1 | 0.12 | ||
| Dickkopf WNT signaling pathway inhibitor 1 | 2.86 | Hypoxia inducible factor 3, alpha | 0.24 | ||
| Myeloid-associated differentiation marker | 2.48 | Phospholipase A2, group IIF | 0.29 | ||
| Microtubule-associated protein 1B | 2.44 | Ciliary neurotrophic factor R | 0.39 | ||
| Parathyroid hormone 1 receptor | 2.42 | C-type lectin domain 2, g | 0.39 | ||
| Cadherin 3 | 2.33 | vanin 1 | 0.43 | ||
| Cadherin 13 | 2.32 | Ca++ channel, voltage-dependent, b 2 | 0.44 | ||
| Adenylate cyclase 3 | 2.17 | Fat atypical cadherin 4 | 0.44 | ||
| gpcr 161 | 2.04 | Glycine decarboxylase | 0.45 | ||
| Fibronectin III domain containing 1 | 2.04 | See above | 0.46 | ||
| Adhesion GPCR G2 | 2.00 | ||||
Genes with significantly altered expression were subjected to gene ontology analysis. GO categories name and code are in the table in bold.
GABA gamma amino butyric acid, GPCR G protein coupled receptor, ECM extracellular matrix, TNF tumor necrosis factor, R receptor, Dom. domain.
Figure 2 Gene ontology (GO) analysis of genes differentially expressed in slc4a11 mouse cornea. The X-axis represents the rank of GO terms based on statistical significance of the alterations of gene expression for genes in a GO category. Numbers beside bars are number of altered genes identified in the pathway/ number of genes in that GO pathway total. Top 20 affected GO category are indicated for: (A) biological process, (B) cellular component, and (C) molecular function.
Figure 3 Kyoto Encyclopedia of Genes and Genomes (KEGG)[4] pathways significantly enriched amongst differentially expressed genes. The X-axis represents the rank of KEGG terms based on statistical significance of the alterations of gene expression for genes in each category. Numbers beside bars are number of altered genes identified in the pathway/number of genes in that KEGG pathway total. Top 20 affected GO pathways are indicated.
Organization of genes with altered expression into functional categories.
Genes with increased expression are written in green text and red indicates decreased expression. Genes in the table are ordered from most to least altered in both the increased and decreased categories. To the right of each gene name are fold changes indicating change of expression in slc4a11 mice relative to slc4a11+. Additional information on the role of each gene and the significance of each alteration can be seen in Suppl Table 1. Functional categories are indicated in bold in the table. Categories are ordered by number genes in each category.
Figure 4Mouse corneal gene expression. Gene expression data from RNAseq were processed to normalize and identify the 102 most abundant transcripts in mouse cornea. Expression of these genes was compared to expression levels of these genes in a panel of 13 mouse tissues (from tissue expression database, https://www.omicsdi.org/dataset/arrayexpress-repository/E-MTAB-6081). Heat map illustrates relative expression level (see inset scale) in cornea and across indicated tissues. * indicates genes not identified as expressed in human CEC (on the basis of genes expressed in isolated human CEC[29,30]) and thus likely expressed in corneal epithelial cells. One of these studies measured transcript abundance in 15 human CEC samples[30]. In this case, we considered genes as expressed in CEC if they were found in 10/15 samples.
Figure 5Comparison of RNAseq and qRT RT-PCR data. Mean values of RNAseq and qRT RT-PCR corresponding to different genes analyzed on slc4a11+ and slc4a11 mice cornea were converted to log2 fold change and used to verify the two methods.